Artelo Biosciences (ARTL) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Key highlights and strategic direction

• Focus on novel lipid signaling modulation therapies targeting anorexia, cancer, anxiety, inflammation, and pain.

• Pipeline includes three main programs: ART-2713 for cancer-related anorexia, ART-2612 for pain and inflammation, and ART-1211 for anxiety and depression.

• Near-term catalysts expected over the next 6, 12, and 18 months, with at least four major clinical milestones anticipated.

• Robust patent estate with nearly 40 patents issued and another 40 pending, providing market exclusivity through at least 2038 for key assets.

• Experienced leadership team with extensive biopharmaceutical development and commercialization background.

Clinical development and pipeline progress

• ART-2713 is in phase 2 for cancer-related anorexia, with data expected early next year; phase 1 showed safety and promising weight gain results.

• ART-2612, a fatty acid-binding protein 5 inhibitor, recently received FDA clearance for phase 1 human studies, targeting chemotherapy-induced peripheral neuropathy.

• ART-1211, a proprietary CBD-TMP co-crystal, targets anxiety and depression, with improved pharmacokinetics and efficacy at lower doses than CBD alone.

• Multiple clinical readouts are expected in the next 12–18 months, including single and multiple ascending dose studies and phase 1/2 data.

• All programs are designed to address significant unmet medical needs in billion-dollar markets.

Financial position and partnership outlook

• Approximately $7 million in cash as of early July, bolstered by R&D tax credits from the U.K.

• Analyst coverage from H.C. Wainwright and other banks, with ongoing interest from global pharmaceutical companies.

• Company has about 3.2 million shares outstanding, fully diluted to nearly 4 million.

• Actively seeking investment and partnership opportunities to support upcoming milestones.

• Confident in financial runway for near-term development, with future funding needs anticipated but not immediate.